Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Different Selexipag Formulations in Healthy Volunteers
NCT05427162Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events up to 114 days, Number of Participants With Serious Treatment-emergent Adverse Events up to 114 days and 1 more. Started Jun 2022; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05427162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427162.